UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 462

Sortiert nach

Real‐world, single‐center experience of SARS‐CoV‐2 vaccination in immune thrombocytopenia

Journal of thrombosis and haemostasis, 2022-06, Vol.20 (6), p.1476-1484

2022

Volltextzugriff (PDF)

Rituximab‐induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of anti‐rituximab antibodies

British journal of haematology, 2019-03, Vol.184 (5), p.858-861

2019

Volltextzugriff (PDF)

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

The New England journal of medicine, 2016-02, Vol.374 (6), p.511-522

2016

Volltextzugriff (PDF)

The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura

British journal of haematology, 2022-07, Vol.198 (2), p.391-396

2022

Volltextzugriff (PDF)

Redefining outcomes in immune TTP: an international working group consensus report

Blood, 2021-04, Vol.137 (14), p.1855-1861

2021

Volltextzugriff (PDF)

The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry

British journal of haematology, 2015-12, Vol.171 (5), p.830-835

2015

Volltextzugriff (PDF)

Characterization and treatment of congenital thrombotic thrombocytopenic purpura

Blood, 2019-04, Vol.133 (15), p.1644-1651

2019

Volltextzugriff (PDF)

Acquired Glanzmann's thrombasthenia with IgG and IgA against activated αIIbβ3

British journal of haematology, 2023-09, Vol.202 (6), p.e58-e61

2023

Volltextzugriff (PDF)

Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era

Blood, 2023-05, Vol.141 (18), p.2206-2213

2023

Volltextzugriff (PDF)

Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy

Blood, 2023-01, Vol.141 (3), p.285-294

2023

Volltextzugriff (PDF)

A single‐center prospective study on the safety of plasma exchange procedures using a double‐viral‐inactivated and prion‐reduced solvent/detergent fresh‐frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy

Transfusion (Philadelphia, Pa.), 2017-01, Vol.57 (1), p.131-136

2017

Volltextzugriff (PDF)

Immune thrombocytopenia in adults: A single‐centre review of demographics, clinical features and treatment outcomes

European journal of haematology, 2020-09, Vol.105 (3), p.344-351

2020

Volltextzugriff (PDF)

Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura

British journal of haematology, 2014-03, Vol.164 (6), p.858-866

2014

Volltextzugriff (PDF)

Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura

British journal of haematology, 2016-06, Vol.173 (5), p.779-785

2016

Volltextzugriff (PDF)

Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel

Acta haematologica, 2021-07, Vol.144 (4), p.418-426

2021

Volltextzugriff (PDF)

Acquired Glanzmann's thrombasthenia with IgG and IgA against activated α IIb β 3

British journal of haematology, 2023-09, Vol.202 (6)

2023

Volltextzugriff (PDF)

Pharmacological venous thromboembolism prophylaxis in elective cranial surgery: a systematic review of time of initiation, regimen and duration

British journal of neurosurgery, 2022-05, Vol.36 (3), p.407-414

2022

Volltextzugriff (PDF)

Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens

Blood advances, 2017-06, Vol.1 (15), p.1159-1166

2017

Volltextzugriff (PDF)

Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune‐mediated thrombotic thrombocytopenic purpura

British journal of haematology, 2019-06, Vol.185 (5), p.912-917

2019

Volltextzugriff (PDF)

Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase

Therapeutic Advances in Hematology, 2022, Vol.13, p.204062072211122-20406207221112217

2022

Volltextzugriff (PDF)

Emerging therapeutics for the treatment of thrombotic thrombocytopenic purpura

Expert opinion on orphan drugs, 2018-10, Vol.6 (10), p.577-584

2018

Volltextzugriff (PDF)

IVIg-exposure and thromboembolic event risk: findings from the UK Biobank

Journal of neurology, neurosurgery and psychiatry, 2022-08, Vol.93 (8), p.876

2022

Volltextzugriff (PDF)

Mycophenolate mofetil therapy for severe immune thrombocytopenia

British journal of haematology, 2015-11, Vol.171 (4), p.625-630

2015

Volltextzugriff (PDF)

Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond

British journal of haematology, 2017-05, Vol.177 (3), p.475-480

2017

Volltextzugriff (PDF)

1 – 25 von 462

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(380)
Mit Volltextzugriff
(388)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(462)
Japanisch
(46)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Archaeologia Cambrensis
(19)
Placenta
(16)
British Journal Of Haematology
(13)
Blood
(12)
Bioorganic & Medicinal Chemistry Letters
(10)
Plos One
(10)
Biology Of Reproduction
(5)
Ethnic And Racial Studies
(5)
Europe-Asia Studies
(5)
Offshore
(5)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Real‐world, single‐center experience of SARS‐CoV‐2 vaccination in immune thrombocytopenia

Rituximab‐induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of anti‐rituximab antibodies

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura

Redefining outcomes in immune TTP: an international working group consensus report

The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry

Characterization and treatment of congenital thrombotic thrombocytopenic purpura

Acquired Glanzmann's thrombasthenia with IgG and IgA against activated αIIbβ3

Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era

Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy

A single‐center prospective study on the safety of plasma exchange procedures using a double‐viral‐inactivated and prion‐reduced solvent/detergent fresh‐frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy

Immune thrombocytopenia in adults: A single‐centre review of demographics, clinical features and treatment outcomes

Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura

Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura

Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura

Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel

Acquired Glanzmann's thrombasthenia with IgG and IgA against activated α IIb β 3

Pharmacological venous thromboembolism prophylaxis in elective cranial surgery: a systematic review of time of initiation, regimen and duration

Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens

Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune‐mediated thrombotic thrombocytopenic purpura

Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase

Emerging therapeutics for the treatment of thrombotic thrombocytopenic purpura

IVIg-exposure and thromboembolic event risk: findings from the UK Biobank

Mycophenolate mofetil therapy for severe immune thrombocytopenia

Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond

Suchergebnisse filtern